AR055594A1 - Prediccion de la recaida osea del cancer de mama - Google Patents

Prediccion de la recaida osea del cancer de mama

Info

Publication number
AR055594A1
AR055594A1 ARP060103349A ARP060103349A AR055594A1 AR 055594 A1 AR055594 A1 AR 055594A1 AR P060103349 A ARP060103349 A AR P060103349A AR P060103349 A ARP060103349 A AR P060103349A AR 055594 A1 AR055594 A1 AR 055594A1
Authority
AR
Argentina
Prior art keywords
prediction
osea
mama
cancer
reception
Prior art date
Application number
ARP060103349A
Other languages
English (en)
Original Assignee
Erasmus Mc Daniel Den Hoed
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Mc Daniel Den Hoed, Veridex Llc filed Critical Erasmus Mc Daniel Den Hoed
Publication of AR055594A1 publication Critical patent/AR055594A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioethics (AREA)
  • Oncology (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)

Abstract

Un método para proporcionar la prediccion de la recaída del cáncer de mama en hueso se realiza analizando la expresion de un grupo de genes; los perfiles de expresion del gen en una variedad de medios tales como microarreglos se incluyen, así como los equipos que los contienen.
ARP060103349A 2005-08-02 2006-08-01 Prediccion de la recaida osea del cancer de mama AR055594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70474005P 2005-08-02 2005-08-02

Publications (1)

Publication Number Publication Date
AR055594A1 true AR055594A1 (es) 2007-08-29

Family

ID=37398743

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103349A AR055594A1 (es) 2005-08-02 2006-08-01 Prediccion de la recaida osea del cancer de mama

Country Status (10)

Country Link
US (1) US20070031873A1 (es)
EP (1) EP1754795A1 (es)
JP (1) JP2007049991A (es)
CN (1) CN1995388A (es)
AR (1) AR055594A1 (es)
AU (1) AU2006203169A1 (es)
BR (1) BRPI0603053A (es)
CA (1) CA2553665A1 (es)
IL (1) IL177006A0 (es)
NZ (1) NZ548655A (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471923B1 (en) 2004-05-28 2014-08-20 Asuragen, Inc. Methods and compositions involving microRNA
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090131348A1 (en) * 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
AU2007299748A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CN101675165A (zh) * 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
KR20100058421A (ko) 2007-05-01 2010-06-03 유니버시티 오브 마이애미 신규 발병 심부전증에 대한 개별 위험 평가용 전사체 바이오마커
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en) * 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US9206482B2 (en) 2009-04-29 2015-12-08 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
WO2010129934A2 (en) 2009-05-07 2010-11-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US11398310B1 (en) 2010-10-01 2022-07-26 Cerner Innovation, Inc. Clinical decision support for sepsis
US10431336B1 (en) 2010-10-01 2019-10-01 Cerner Innovation, Inc. Computerized systems and methods for facilitating clinical decision making
US10734115B1 (en) 2012-08-09 2020-08-04 Cerner Innovation, Inc Clinical decision support for sepsis
US11348667B2 (en) 2010-10-08 2022-05-31 Cerner Innovation, Inc. Multi-site clinical decision support
US10628553B1 (en) 2010-12-30 2020-04-21 Cerner Innovation, Inc. Health information transformation system
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US8856156B1 (en) 2011-10-07 2014-10-07 Cerner Innovation, Inc. Ontology mapper
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US10249385B1 (en) 2012-05-01 2019-04-02 Cerner Innovation, Inc. System and method for record linkage
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US10946311B1 (en) 2013-02-07 2021-03-16 Cerner Innovation, Inc. Discovering context-specific serial health trajectories
US10769241B1 (en) 2013-02-07 2020-09-08 Cerner Innovation, Inc. Discovering context-specific complexity and utilization sequences
US11894117B1 (en) 2013-02-07 2024-02-06 Cerner Innovation, Inc. Discovering context-specific complexity and utilization sequences
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3010401A4 (en) * 2013-06-20 2017-03-15 University Of Virginia Patent Foundation Multidimensional time series entrainment system, method and computer readable medium
US10483003B1 (en) 2013-08-12 2019-11-19 Cerner Innovation, Inc. Dynamically determining risk of clinical condition
US12020814B1 (en) 2013-08-12 2024-06-25 Cerner Innovation, Inc. User interface for clinical decision support
US10957449B1 (en) 2013-08-12 2021-03-23 Cerner Innovation, Inc. Determining new knowledge for clinical decision support
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
EP3451927A4 (en) * 2016-05-02 2020-01-01 University Of Virginia Patent Foundation METHOD, SYSTEM, AND COMPUTER-READABLE MEDIUM FOR GENERATING PREDICTIVE PULSOXIMETRY SCORES (POPS) FOR EARLY BIRTH
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
CN108977547B (zh) * 2018-08-14 2019-05-28 江门市中心医院 Tspan1在乳腺癌转移的诊断、预后及治疗中的应用
CN110423816B (zh) * 2018-10-12 2023-06-27 天津医科大学肿瘤医院 乳腺癌预后量化评估系统及应用
MX2021006560A (es) * 2018-12-08 2021-11-17 Pfs Genomics Inc Perfilado transcriptómico para prognosis de cáncer de mama.
JP2022537052A (ja) * 2019-06-21 2022-08-23 カーナル バイオロジクス， インコーポレイテッド 操作された腫瘍選択的タンパク質発現
KR102204958B1 (ko) 2019-10-28 2021-01-20 삼성에스디에스 주식회사 의료 검사 결과 데이터의 처리 방법
US11730420B2 (en) 2019-12-17 2023-08-22 Cerner Innovation, Inc. Maternal-fetal sepsis indicator
CN115350187B (zh) * 2022-08-30 2023-08-29 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用
CN116064663A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rps基因促进载体稳定表达的方法及其功能基因

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136182A (en) 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
AU3035699A (en) * 1998-03-27 1999-10-18 Seibel, Markus Determination of the probability of bone metastases in patients with primary carcinomas
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7363165B2 (en) 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
US20020068691A1 (en) * 2000-06-21 2002-06-06 Susana Salceda Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7087727B2 (en) * 2001-08-13 2006-08-08 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
CA2497873A1 (en) * 2002-09-05 2004-03-18 Garvan Institute Of Medical Research Novel diagnostic and therapeutic methods and reagents therefor
AU2005212401A1 (en) * 2004-02-06 2005-08-25 Health Research, Inc. Method of prognosis of metastasis by detection of FRA12E fragile site within the SMRT gene/locus at chromosome 12q24
EP1721159B1 (en) 2004-02-20 2014-12-10 Janssen Diagnostics, LLC Breast cancer prognostics
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development

Also Published As

Publication number Publication date
CN1995388A (zh) 2007-07-11
BRPI0603053A (pt) 2007-03-20
JP2007049991A (ja) 2007-03-01
AU2006203169A1 (en) 2007-02-22
IL177006A0 (en) 2006-12-10
EP1754795A1 (en) 2007-02-21
US20070031873A1 (en) 2007-02-08
CA2553665A1 (en) 2007-02-02
NZ548655A (en) 2009-01-31

Similar Documents

Publication Publication Date Title
AR055594A1 (es) Prediccion de la recaida osea del cancer de mama
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
MX2018006148A (es) Inhibidores de cxcr2.
EA201492114A1 (ru) Композиции и способы для модулирования экспрессии генов
CL2017002637A1 (es) Compuestos nucleósidos 5'-sustituidos.
GT201200134A (es) Decodificación mejorada de flujos de bits codificados de audio multicanales utilizando transformación híbrida adaptativa
BR112017009754A2 (pt) processo para produção de hexanotriol a partir de 5-hidroximetfilfurfural
MX340453B (es) Biomarcadores para cancer de pulmon.
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
BRPI0518734A2 (pt) prognàstico de cÂncer de pulmço
ECSP11011466A (es) Anticuerpos específicos para cadherina-17
EA201400984A2 (ru) Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
MY184101A (en) Indoles
IN2012DN02485A (es)
AR090717A1 (es) Metodo para la formacion de alotropos de carbono
ECSP099049A (es) Nuevas indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
ECSP11011433A (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
CL2014000922A1 (es) Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros.
ECSP11011245A (es) Novedosos herbicidas
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
MX2017013749A (es) Composiciones y metodos para construir genotecas de adnc especificas de hebra.
CR20130106A (es) Nuevos moduladores de trpv3
EA201490823A1 (ru) Агенты, реверсирующие действие антикоагулянтов

Legal Events

Date Code Title Description
FB Suspension of granting procedure